Partner Headlines - BMRN

  1. Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?

    Investors Business Daily
  2. Biotechs Unhinged By Tough Pricing Talk

    TalkMarkets
  3. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech? ...

    TalkMarkets
  4. Stock Exchange: Is Technical Analysis Effective Post-Election?

    TalkMarkets
  5. Biogen Upgraded To Overweight From Neutral At Piper Jaffray

    TalkMarkets
  6. Weighing the Week Ahead: Time for Some Clarity?

    TalkMarkets
  7. Stock Exchange: Contrarian Pre-Election Trade Ideas In Chips, ...

    TalkMarkets
  8. Contrarian Pre-Election Trade Ideas In Chips, Biotech, Trucking, ...

    TalkMarkets
  9. Seattle Genetics (SGEN) Loss Narrower Than Expected In Q3

    TalkMarkets
  10. J&J Outshines in Q3 Earnings on Strong Pharma Sales

    TalkMarkets
  11. Swing Trading Watch List - October 11, 2016

    TalkMarkets
  12. Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD

    IBD
  13. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus
  14. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing ...

    Benzinga
  15. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD
  16. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD
  17. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial ...

    Benzinga
  18. BioMarin, Intercept hit by FDA

    IBD
  19. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD
  20. BioMarin Announces That FDA Has Advised it Will Not Take Action ...

    Benzinga
  21. Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' ...

    GuruFocus
  22. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD
  23. FDA Advisory Committee Discusses Clinical Data Package for BioMarin's ...

    Benzinga
  24. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD
  25. BIOMARIN PHARMA

    IBD
  26. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD
  27. Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

    Benzinga
  28. Morning Market Losers

    Benzinga
  29. Benzinga's Top #PreMarket Losers

    Benzinga
  30. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  31. Benzinga's Top Initiations

    Benzinga
  32. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  33. Hurricane Hillary Shifts Left, Slamming More Stocks

    IBD
  34. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD
  35. BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide ...

    Benzinga
  36. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD
  37. BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise ...

    Benzinga
  38. Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical ...

    Benzinga
  39. Stocks Rally, Will Gains Hold? Biotechs Try Second Rebound

    IBD
  40. Benzinga's Top #PreMarket Losers

    Benzinga
  41. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  42. BioMarin Announces Two Oral and 19 Poster Presentations at the ...

    Benzinga
  43. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    GuruFocus
  44. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga
  45. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    Benzinga
  46. BioMarin Receives Rare Pediatric Disease Designation From FDA ...

    Benzinga
  47. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD
  48. 2 DMD drugs make progress

    IBD
  49. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  50. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  51. Benzinga's Volume Movers

    Benzinga
  52. Benzinga's Top Downgrades

    Benzinga
  53. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  54. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  55. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  56. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  57. Benzinga's Volume Movers

    Benzinga
  58. Morning Market Gainers

    Benzinga
  59. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  60. Benzinga's Top #PreMarket Gainers

    Benzinga
  61. BIOMARIN PHARMA

    IBD
  62. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  63. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  64. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  65. Benzinga's Top Initiations

    Benzinga
  66. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  67. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  68. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  69. BIOMARIN PHARMA

    IBD
  70. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  71. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  72. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  73. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  74. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  75. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  76. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  77. BIOMARIN PHARMA

    IBD
  78. State Of The Union Lights Up Biotech

    Benzinga
  79. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  80. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  81. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  82. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  83. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  84. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  85. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  86. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  87. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  88. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  89. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  90. BioMarin buying Prosensa

    IBD
  91. Trio Of Major Deals Disclosed

    IBD
  92. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  93. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  94. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  95. Benzinga's Volume Movers

    Benzinga
  96. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  97. Stocks Hitting 52-Week Highs

    Benzinga
  98. Morning Market Movers

    Benzinga
  99. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  100. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
Trading Center